PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences. The UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 am ET; andThe Stifel 2025 Healthcare... Read more
Oncoguard® Liver blood test delivers seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care
ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups MADISON, Wis. / Nov 07, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today... Read more
NEW YORK / Nov 07, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies 2025 London Healthcare Conference.
Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, November 19, 2025... Read more
WARSAW, Ind., Nov. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025, at Noon GMT (7 a.m. ET).
A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The... Read more
PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions
Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter and provided a corporate update.
The... Read more
Revenue of $84.1 million, growing 17% year-over-year
Raising Full Year 2025 Revenue Guidance to $325.0 million
Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ($1.70) per share and Non-GAAP income of $0.30 per share
GAAP gross profit of $35.5 million, or GAAP gross margin of 42.2%; Non-GAAP gross profit of $37.2 million, or Non-GAAP gross margin of 44.3%
GAAP loss of $6.6 million, or ($0.21) per share; Non-GAAP income of $4.5 million, or $0.14 per... Read more
Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.
Announces record multi-system order... Read more
Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history.
Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024.
GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024.
Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov.... Read more
Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2025.
Third... Read more
Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment of Intracranial Bleeding SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 6, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced... Read more
AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basis
Base business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basis
GAAP net... Read more
Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability SOUTH ORANGE, NJ., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2025.
Financial Highlights
Net revenue increased 35% to $4.8 million... Read more
Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity
Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter... Read more
BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included.
Q3 2025: Sales $61.0mm,... Read more
SAN CLEMENTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2025.
Third Quarter 2025 Results
Third quarter 2025 revenue was $537.0 million, as compared to $589.1 million in the same period in the prior year. GAAP gross profit for the third quarter of 2025 was $200.9 million, as compared... Read more
VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2025.
Financial Results Commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024.
Cash, cash equivalents, and marketable securities... Read more
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year... Read more
PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025.
Recent Highlights Generated revenue of $50.2 million in third quarter 2025 representing growth of 11% over the same period in 2024.&... Read more
Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis
Net income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025
Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared... Read more
AUSTIN, Texas / Nov 06, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025.
Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period.
Generated a gross margin... Read more
SAN DIEGO / Nov 06, 2025 / Business Wire / Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance.
Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally
Demonstrated year-over-year and sequential gross margin improvement
Progressed... Read more
Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer
Revenues of $6.9 million
Shipped 16 SRT systems including three to China
Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter
Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today
BOCA RATON, Fla. / Nov 06, 2025 / Business Wire /... Read more
Cell Processing revenue of $25.4 million, up 33% over Q3 2024
GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64%
GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million or 28% of revenue
Raises 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million; Full-year total revenue guidance to $95.0 - $96.0 million, adjusted for the recent sale of its evo cold chain logistics subsidiary
Conference call begins... Read more
RA'ANANA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has completed the regulatory submission of its FDA-cleared INSPIRA™ ART100 system (“ART100”) to the United Arab Emirates Ministry of Health and Prevention (“MOHAP”). Final approval is expected within days, marking... Read more
LINCOLN, Neb. & TUPELO, Miss. / Nov 06, 2025 / Business Wire / North Mississippi Health Services (NMHS), a regional leader serving 24 counties across north Mississippi and northwest Alabama, has selected NRC Health as its long-term partner in healthcare experience management and strategic improvement.
Through its eight North Mississippi Medical Center hospitals, more than 70 primary and specialty care clinics, four nursing homes, and telehealth services, NMHS has a long... Read more
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight®... Read more
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service Expansion
Comprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, today announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand. The Company... Read more
Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer
Longitudinal circulating tumor DNA (ctDNA) monitoring across multiple timepoints provides a more accurate prediction of treatment response and disease progression than a single on-treatment analysis, reinforcing the clinical value of serial testing PALO ALTO, Calif. / Nov 06, 2025 / Business Wire / Guardant Health,... Read more
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address key limitations of targeted RNA-sequencing (RNA-seq) panels in detecting therapeutically-relevant gene rearrangements in acute leukemias. This peer-reviewed publication, entitled “Comparative Analysis of Targeted RNA-Seq and Optical... Read more
EXRAY, leading Czech radiography supplier with 50%+ market penetration, to distribute Nanox’s imaging solutions PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a distribution agreement with EXRAY s.r.o (“EXRAY”), a leading Czech distributor of medical imaging systems, to introduce Nanox’s advanced imaging solutions... Read more
Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its CY 2026 Medicare Physician... Read more
ATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA") in the treatment of acute and chronic arch pathologies. The trial is designed to support the Company's forthcoming application to the U.S. Food... Read more
CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney SOUTH SAN FRANCISCO, Calif. / Nov 06, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today... Read more
18 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025
ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today... Read more
Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 million
Separately announced upcoming retirement of CEO, departure of President and appointment of prior CEO to Executive Chairperson; Board conducting CEO search
Announced PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent; for MK-6240, its F 18... Read more
Net revenue growth accelerated to 15% year over year
Active Customers growth accelerated to 9% on a trailing 12-month basis NEW YORK / Nov 06, 2025 / Business Wire / Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025.
“This was a strong quarter for our team as we advanced our strategic priorities and... Read more
Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organic
Q4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectively
FY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organic
FY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%
FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD Excellence
FY25 GAAP operating margin... Read more
Raises Full Year Revenue and Margin Guidance ACTON, Mass. / Nov 06, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025.
Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency1, and exceeded the high end... Read more
Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance PIOMBINO DESE, Italy / Nov 06, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025.
Third Quarter 2025... Read more
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025.
Third quarter financial summary GAAP revenue of $913.0, up 19.4% compared to the prior year period
Adjusted revenue of $892.9 million, up 16.8% compared to the prior year period, and up 15.3% on an adjusted constant currency basis1
GAAP diluted EPS from continuing operations of $(9.24),... Read more
Financial release and supplemental presentation accessible online BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.... Read more
Revenue of $274.1 million in Q2, ahead of outlook
Diluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09
Repurchased approximately 1.1 million shares opportunistically in Q2
Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial... Read more
CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the... Read more
New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of... Read more
MISSISSAUGA, Ontario / Nov 06, 2025 / Business Wire / MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, further to its Press Release dated October 6, 2025, announcing an Initial Closing, it has completed final Closings of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated July 25, 2025. The Final Closings comprised the issuance of 19,106,666 Units (as described below) and raised... Read more
Initiated full U.S. commercial launch of AYON Body Contouring System™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations
Submitted new 510(k) for AYON for device label expansion to include power liposuction
Increased total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million
Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX)... Read more
Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations
Company Expects to Refinance or Repay the Debt in the Fourth Quarter
Fourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter and nine months... Read more
EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes
167% YoY Growth in Focal One System Placements
15% YoY Growth in U.S. Focal One HIFU Procedures
Company to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated... Read more
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases.
Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed... Read more
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will participate in the following investor conferences:
2025 UBS Global Healthcare Conference - Palm Beach Gardens, FL
Presenting on Monday, November 10, 2025
2025 Stifel Healthcare Conference - New York, NY
Presenting on Thursday,... Read more
